efficacy and safety of sotagliflozin versus glimepiride and placebo in participants with type 2 diabetes mellitus that are taking metformin monotherapy

Conditions: Type 2 Diabetes Mellitus

Summary: primary objective: to demonstrate the non-inferiority of sotagliflozin 400 milligrams (mg) compared to glimepiride on hemoglobin a1c (hba1c) reduction at week 52 in participants with type 2 diabetes (t2d) who have inadequate glycemic control with metformin. secondary objectives: to demonstrate the superiority of sotagliflozin 400 mg compared to glimepiride on change in body weight, systolic blood pressure (sbp) in participants with baseline sbp ≥130 millimeter of mercury (mmhg), sbp in all participants, and proportion of participants with at least 1 documented symptomatic hypoglycemic event (≤70 milligrams per deciliter \[mg/dl\]). * to demonstrate the superiority of sotagliflozin 400 mg compared to placebo on change in hba1c, body weight, sbp in participants with baseline sbp ≥130 mmhg, sbp in all participants. * to demonstrate the superiority of sotagliflozin 200 mg compared to placebo on change in hba1c. * to demonstrate the non-inferiority of sotagliflozin 400 mg compared to glimepiride on change in hba1c. * to demonstrate the superiority of sotagliflozin 400 mg compared to glimepiride on change in hba1c. * to evaluate the safety and tolerability of sotagliflozin compared to glimepiride and placebo.

up to 58 weeks, including a screening period consisting of a screening phase of up to 2 weeks, a 2-week single-blind placebo run-in phase, a 52-week double-blind treatment period, and a 2-week post-treatment follow-up period to collect safety information.

Eligibility criteria:
inclusion criteria : * participants with type 2 diabetes (t2d) treated with metformin at a stable dose ≥1500 milligrams per day (mg/day) or maximum tolerated dose (documented) for at least 12 weeks prior to screening visit; in case of documented lack of tolerance, metformin dose \<1500 mg/day is acceptable, and the dose should be stable for at least 12 weeks prior to screening visit. * participants has given written informed consent to participate in the study in accordance with local regulations. exclusion criteria: * age \<18 years at the screening visit or \<legal age of majority, whichever is greater. * type 1 diabetes mellitus. * hba1c, hba1c \ 10% at screening. * fasting plasma glucose (fpg) \>15 millimoles per liter (mmol/l) (\>270 milligram per deciliter \[mg/dl\]) measured by the central laboratory at screening (visit 1) and confirmed by a repeat test (\>15 mmol/l \[\>270 mg/dl\]) before randomization. * body mass index ≤20 or \>45 kilogram per meter square (kg/m\^2) at screening. * pregnant (confirmed by pregnancy test at the screening) or breast-feeding women. * women of childbearing potential (wocbp) not willing to use highly effective method(s) of birth control during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy (see appendix a) during the study. * previous use of any antidiabetic drug other than metformin within 12 weeks preceding the screening visit. * use of a selective sodium-glucose co-transporter-2 (sglt2) inhibitor (e.g., canagliflozin, dapagliflozin, or empagliflozin) within 3 months prior to the screening visit. * use of systemic glucocorticoids (excluding topical, or ophthalmic application, intra-articular, nasal spray or inhaled forms) for more than 10 consecutive days within 90 days prior to the screening visit. * previous insulin use \>1 month (at any time, except for treatment of gestational diabetes). * history of prior gastric surgical procedure, including gastric banding, or inflammatory bowel disease within 3 years prior to the screening visit. * difficulty swallowing such that the participants cannot take the investigational medicinal product (imp). * history of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the screening visit. * mean of 3 separate blood pressure measurements \>180 millimeter of mercury (mmhg) (sbp) or \>100 mmhg (dbp). * history of hypertensive emergency within 12 weeks prior to screening. * participants who have previously been randomized in any clinical trial of sotagliflozin/lx4211. * participants with severe renal disease as defined by an estimated glomerular filtration rate (egfr) of \<30 milliliter per minute per meter square (ml/min/1.73 m\^2) at screening, based on the 4 variable modification of diet in renal disease (mdrd) equation (or according to the renal function restrictions of metformin use defined in the local approved label). * participants with severe anemia, severe cardiovascular (including congestive heart failure new york heart association iv), respiratory, hepatic, neurological, psychiatric, or active malignant tumor or other major systemic disease that, according to investigator, will preclude their safe participation in this study, or will make implementation of the protocol or interpretation of the study results difficult. * aspartate aminotransferase and/or alanine aminotransferase: \>3 times the upper limit of the normal laboratory range (uln). * total bilirubin: \>1.5 times uln (except in case of gilbert's syndrome). * participants who have taken other investigational drugs within 12 weeks or 5 half-lives from screening whichever is longer. * participants unwilling or unable to perform self-monitoring blood glucose (smbg), complete the participant diary, or comply with study visits and other study procedures as required per protocol. * participants with contraindication to glimepiride as per local labelling. * participants with contraindication to metformin as per local labelling. the above information is not intended to contain all considerations relevant to a participants potential participation in a clinical trial.